James Bucher
General Counsel bei HARPOON THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
James B.
Bucher currently works at Harpoon Therapeutics, Inc., as Chief Legal Officer from 2023.
Mr. Bucher also formerly worked at Exelixis, Inc., as Secretary & Vice President-Corporate Legal Affairs from 2013 to 2014, Shearman & Sterling LLP, as Partner from 2001 to 2007, Lundbeck Seattle BioPharmaceuticals, Inc., as Executive Vice President & General Counsel, and Eliem Therapeutics, Inc., as Executive Vice President & General Counsel.
Mr. Bucher received his undergraduate degree from Colgate University and graduate degree from Emory University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 31.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von James Bucher
| Unternehmen | Position | Beginn |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | General Counsel | 26.12.2023 |
Ehemalige bekannte Positionen von James Bucher
| Unternehmen | Position | Ende |
|---|---|---|
| EXELIXIS, INC. | General Counsel | 01.01.2014 |
Shearman & Sterling LLP
 Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2007 |
| ELIEM THERAPEUTICS, INC. | General Counsel | - |
| ALDER BIOPHARMACEUTICALS, INC. | General Counsel | - |
Ausbildung von James Bucher
| Emory University School of Law | Graduate Degree |
| Colgate University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| HARPOON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Shearman & Sterling LLP
Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Commercial Services |
